Insulin (Long-Acting)

LANTUS labeling warns that severe hypoglycemia can cause seizures or death, and its long action may delay recovery from hypoglycemia. Changing insulin type or concentration can alter glucose control.^[2]

• Direct label evidence for glargine U-100; the directory category also includes other products with different properties.

Insulin can cause life-threatening hypoglycemia; HUMALOG labeling separately states that all insulins, including HUMALOG, can cause a shift in potassium that may lead to hypokalemia, which can cause respiratory paralysis, ventricular arrhythmia and death. HUMALOG labeling requires close medical supervision for regimen changes. Rapid- and long-acting insulin may be prescribed together; their presence alone is not a contraindicated combination.^[4]

• Insulin formulations have different action profiles; the inspected product label is HUMALOG.
• This site does not calculate insulin doses or provide a rescue regimen.

Call the local emergency number (911 in the US) for collapse, inability to breathe or unresponsiveness. For suspected poisoning, get help immediately; in the US call Poison Help at 1-800-222-1222. Do not give an unconscious person anything by mouth, and do not induce vomiting unless instructed by poison control or a health care professional.^[10][11]

• General first-aid guidance, not a complete symptom list or treatment protocol; use local emergency services outside the US.

A glucose-clamp trial found that the action profiles of glargine and detemir differed between single-dose and steady-state testing and between individuals. A single universal duration for all long-acting insulins is misleading.^[1]

• Glucose-lowering duration is not elimination half-life; dose, study method and insulin product matter.
• Abstract-checked; no qualified clinical review. Full text remains paywalled (Wiley); a public copy could not be lawfully obtained on the access date.

Somatropin can reduce insulin sensitivity. GENOTROPIN labeling states this directly and warns that antihyperglycemic drug doses, including insulin, may need adjustment; HUMALOG's own drug-interaction table separately names somatropin among agents that may decrease HUMALOG's glucose-lowering effect. This does not establish an additive hypoglycemia effect of growth hormone.^[3][4]

• The insulin records group multiple preparations; the inspected insulin label is HUMALOG (lispro).
• These passages do not test research secretagogues.
• Somatropin appears only as one named example within a long generic drug-class list in HUMALOG's table; it is not a dedicated somatropin/lispro trial.

OZEMPIC labeling warns that concomitant insulin can increase hypoglycemia risk and may require clinician-directed insulin adjustment. In SUSTAIN 5, semaglutide improved glycemic control on basal insulin; the trial pre-emptively reduced participants' insulin dose 20% at entry, and the numerical excess in hypoglycemia was not statistically conclusive.^[5][6]

• A supervised diabetes combination can have clinical benefit; this is not a blanket prohibition.
• The trial did not establish a doubling of risk, and its own protocol-mandated insulin-dose reduction at entry limits comparison to unmodified add-on use.

ZEPBOUND labeling warns of increased hypoglycemia risk when tirzepatide is used with insulin and calls for consideration of a clinician-directed insulin reduction.^[7]

• A label warning for insulin coadministration, not a separate trial of every insulin preparation.

MK-677 reduced insulin sensitivity in an older-adult trial, and somatropin labeling warns of reduced insulin sensitivity. These individual-agent findings motivate a possible glycemic concern; the combination and its magnitude were not tested.^[8][3]

• MK-677 results cannot be assigned to every GHRH or ghrelin-related peptide.
• Does not establish additive hypoglycemia with insulin.

In hemodialysis patients, intravenous insulin with glucose plus nebulized albuterol lowered potassium more than either treatment alone; the same study reports that albuterol blunted, rather than added to, insulin's glucose-lowering (hypoglycemic) effect. Application to the rapid- or long-acting insulin records is a formulation and route extrapolation.^[9]

• The inspected abstract does not identify an insulin analogue; this result cannot be presented as an exact study of lispro or glargine.
• Does not establish a quantitative clenbuterol interaction.
• This 1990 study describes a deliberate, supervised hyperkalemia treatment, not an adverse interaction; the potassium-lowering axis is distinct from the separate glucose-lowering-effect axis now also documented in HUMALOG's own label (see ix-insulin-albuterol-glycemic).

CYTOMEL labeling states that adding liothyronine (T3) therapy in patients with diabetes mellitus may worsen glycemic control and result in increased antidiabetic-agent or insulin requirements, and recommends monitoring glycemic control when liothyronine is started, changed or discontinued.^[12]

• A drug-class label warning naming “antidiabetic agent or insulin requirements” generically, not a named insulin-analogue trial.
• Does not establish a numeric hypoglycemia or hyperglycemia magnitude for this specific pair.

HUMALOG's drug-interaction table names albuterol as an example of a sympathomimetic agent that may decrease HUMALOG's blood-glucose-lowering effect, and recommends dose adjustment and increased glucose monitoring when these are coadministered.^[4]

• Albuterol is named as one example within a long generic drug-class list in the label, not an isolated albuterol trial.
• Describes a glucose-lowering-effect axis distinct from the potassium-lowering effect covered by ix-insulin-albuterol-potassium.